Latest Conference Articles

Elizabeth Swisher, M.D., discusses the ARIEL2 study, which proved that rucaparib may be a promising agent for patients with recurrent ovarian cancer.

Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.